enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Empagliflozin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin

   Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and works by increasing sugar loss in urine. [2] Empagliflozin was approved for medical use in the United States and in the European Union in 2014. [13] [23] [24] It is on the World Health Organization's List of Essential Medicines. [25]

3. Are Diabetes Drugs Really Safe (& Reliable) for Weight Loss?

   www.aol.com/diabetes-drugs-really-safe-reliable...

   GLP-1 drugs for weight loss and type 2 diabetes include dulaglutide, liraglutide, and semaglutide. GIP/GLP-1s. These are dual-acting, meaning they target two receptors in the body: gastric ...

4. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Empagliflozin, approved in the United States in August 2014, under the brand name Jardiance by Boehringer Ingelheim. [30] Of the gliflozins, empagliflozin and tofogliflozin have the highest specificity for SGLT2 inhibition. [1] This oral medicine for type 2 diabetes has been shown to reduce the risk of cardiovascular death. [31]

5. 4 of the Top Prescription Weight Loss Pills & How They Work - AOL

   www.aol.com/4-top-prescription-weight-loss...

   Regular physical activity can help accelerate weight loss, improve metabolism and enhance the benefits of weight loss pills. Aim for 150 minutes per week (or about a half-hour five days a week).

6. Weight Loss Injections: What You Need to Know, From ... - AOL

   www.aol.com/lifestyle/weight-loss-injections...

   Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes medications — also known as GLP-1 and GIP injections — are changing the ...

7. Diabetes medication - Wikipedia

   en.wikipedia.org/wiki/Diabetes_medication

   GLP-1 analogs resulted in weight loss and had more gastrointestinal side-effects, while in general dipeptidyl peptidase-4 (DPP-4) inhibitors were weight-neutral and are associated with increased risk for infection and headache. Both classes appear to present an alternative to other antidiabetic drugs.